Related Experiment Video
Updated: May 28, 2026
09:49
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
Variant e19a2 BCR-ABL1 fusion transcript in typical chronic myeloid leukemia
Andreea Cristina Tutulan-Cunita1, Sorina Mihaela Chirieac, Gabriela Mocanu
1"Victor Babes" National Institute of Pathology, Bucharest, Romania. andreea.cunita@ivb.ro
Clinical Laboratory
|October 28, 2011
Summary
This study reports a rare case of chronic myeloid leukemia (CML) with the e19a2 fusion transcript. Understanding this rare CML variant is crucial for prognosis and treatment.
Area of Science:
- Hematology
- Oncology
- Molecular Genetics
Background:
- Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene, resulting from the t(9;22) translocation.
- Over 15 BCR-ABL1 fusion transcripts exist, with e19a2 being a rare variant first identified in 1990.
Observation:
- A 38-year-old male presented with CML and underwent genetic analysis.
- Karyotyping and molecular investigations confirmed the t(9;22) translocation in all metaphases.
Findings:
- The patient's BCR-ABL1 fusion gene exhibited the rare e19a2 transcript without sequence alterations.
- This case adds to the limited documented instances of CML with the e19a2 transcript.
Implications:
- CML with e19a2 transcript presents diverse clinical features and uncertain biological significance.
- Further case studies are essential to elucidate the mechanisms, prognosis, and optimal management of this rare CML subtype.
